Although a selective FGFR2 inhibitor has been shown to be more sensitive to FGFR2-amplified GC cell-lines, there are four ongoing clinical trials (NCT01719549, NCT01921673, NCT02052778, and NCT02318329) to assess the efficacy in actual patients [22]. The gene discussed is FGFR2; the disease is gastric cancer.